McKesson Corporation
MCK Healthcare Medical Distribution
McKesson Corporation’s revenue for fiscal 2026 (year ended March 2026) was $403.4 billion, up 12.4% from fiscal 2025. In the quarter to June 2026, revenue grew 7.72%, EPS fell 17.7%, free cash flow grew 66.4% and total debt rose 10.5%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for ten.
Follow MCK
McKesson Corporation (MCK) EBITDA
McKesson Corporation's EBITDA for fiscal 2026 was $6.9B, up 37.2% from $5.1B in fiscal 2025. Over the twelve months to 30 June 2026 it was $7.3B. Over the past ten years it has ranged from −$3.9B (fiscal 2021) to $8.3B (fiscal 2017); the current reading is higher than 92% of that period. McKesson Corporation ranks 1st of 10 Medical Distribution companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2026 | $6.9B | 37.23% |
| FY2025 | $5.1B | 11.31% |
| FY2024 | $4.5B | (8.92%) |
| FY2023 | $5.0B | 78.31% |
| FY2022 | $2.8B | — |
| FY2021 | −$3.9B | — |
| FY2020 | $3.6B | (9.30%) |
| FY2019 | $3.9B | (0.41%) |
| FY2018 | $3.9B | (52.78%) |
| FY2017 | $8.3B | 87.52% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $1.5B | (35.46%) |
| Mar 2026 | $2.3B | 29.83% |
| Dec 2025 | $1.8B | 13.29% |
| Sep 2025 | $1.6B | 33.70% |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| MCK McKesson Corporation | $7.3B |
| COR Cencora, Inc. compare | $4.1B |
| CAH Cardinal Health, Inc. compare | $3.6B |
| HSIC Henry Schein, Inc. compare | $1.0B |
| ACH Accendra Health, Inc. compare | $285.4M |
| COSM Cosmos Health Inc. compare | −$16.9M |
| FOCL FocalTherics compare | −$25.3M |
| AHG Akso Health Group Sponsored ADR compare | −$30.3M |
| HKPD Cellyan Biotechnology Co., Ltd compare | — |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on MCK
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement